NCT02948569View on ClinicalTrials.gov

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

December 18, 2017

Study Completion Date

January 30, 2019

Conditions
Metabolic Syndrome
Interventions
DRUG

3-V Bioscience-2640

Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.

Trial Locations (1)

65201

University of Missouri, Columbia

All Listed Sponsors
collaborator

Sagimet Biosciences Inc.

INDUSTRY

lead

University of Missouri-Columbia

OTHER

NCT02948569 - Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome | Biotech Hunter | Biotech Hunter